Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Interleukin"

Clazakizumab for Adults with Active PsA

Arthritis & Rheumatology  |  August 30, 2016

This is the first clinical trial of an IL-6–targeted therapy in PsA. Clazakizumab may be an effective treatment option for musculoskeletal aspects of PsA, but because of the lack of a dose response in this study, further studies are required to confirm the appropriate dose. The safety profile is consistent with the pharmacology of IL-6 blockade and prior clinical experience with this antibody in rheumatoid arthritis…

Secukinumab Effective for Treating Psoriatic Arthritis

Reuters Staff  |  July 15, 2015

NEW YORK (Reuters Health)—The anti-interleukin-17A monoclonal antibody secukinumab improves signs and symptoms in patients with psoriatic arthritis, according to results from Novartis’ FUTURE 2 trial. In earlier studies, secukinumab has demonstrated superior effectiveness to placebo and etanercept in improving the signs and symptoms of psoriasis. Dr. Iain B. McInnes from the University of Glasgow in…

Interleukin 1-alpha Is Critical for Establishment of Inflammatory Lung Disease

Lara C. Pullen, PhD  |  January 21, 2014

New research clarifies the role of fibroblasts in chronic lung disease.  (posted Jan. 21)

Neutralizing IL-23 and Its Targets May Improve Ankylosing Spondylitis

Lara C. Pullen, PhD  |  August 30, 2012

Researchers have identified a unique population of entheseal resident cells that can be activated by interleukin 23 (IL-23). This finding may be key to understanding how dysregulation of IL-23 results in precise inflammation of the entheses.

Research on IL-17 Cytokine May Lead to Novel Therapies for RA

From the College  |  October 1, 2010

Research in the laboratory of John D. Mountz, MD, PhD, is opening up a whole new field of study in rheumatoid arthritis (RA).

Rheum with a View: Perspectives on Selections from the Literature

Richard S. Panush, MD  |  September 1, 2010

Perspectives on selections from the literature

French Scientist Honored with International Award

Sarah Gelotte  |  September 1, 2010

Pierre Miossec, MD, of the department of immunology and rheumatology at the Hospital Eduoard Herriot and professor of clinical immunology of Claude Bernard University, both in Lyon, France, was awarded the Carol Nachman Prize for Rheumatology this May in Wiesbaden, Germany. The award promotes clinical, therapeutic, and experimental studies in rheumatology and is the highest international honor for rheumatology research. Dr. Miossec, a long-time researcher of the role of cytokines in rheumatoid arthritis (RA), was honored for his discoveries of the functions of the T cell–derived cytokine interleukin-17 (IL-17) in this inflammatory disease.

The Expanded Role of the Inflammasome in Human Disease

Alexander So, MD, and Borbála Pazár, MD, PhD  |  August 1, 2010

Exploring advances, evaluating what remains to be done

Immune System No Longer Autonomous?

Gretchen Henkel  |  May 1, 2010

Evolving model has implications for novel therapies

Decoding Autoinflammatory Syndromes

Kathy Holliman  |  January 1, 2010

Understanding the genetic basis of errors of the immune system may provide new opportunities for therapy

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences